Initial Focus on the Development of an NGS-Based Cancer Panel
Fremont, CA /PRNewswire/ - WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today a commercial partnership with Molecular Pathology Laboratory Network, Inc. (MPLN) with the goal of developing Next-Generation sequencing (NGS) based clinical tests.
"One of the key challenges in developing clinical grade targeted NGS panels is achieving complete coverage of the required genes. Based on my experience, WaferGen's target enrichment technology offers a unique solution that not only provides adequate coverage, but also reduces the number of steps in sample preparation. We feel that this is ideal for our clinical lab setting," stated Dr. Jamie Platt, Vice President of Genomic Solutions at MPLN. "The first product to be commercialized through this commercial partnership is a solid tumor panel to complement MPLN's Pathology Partners Program and support the expanding Molecular Oncology Services menu," added Dr. Platt.
"Partnership with MPLN is the latest example of the adoption of the Seq-Ready™ version of our SmartChip TE™ system by a major clinical reference lab. We believe that SmartChip TE™ is the solution of choice for clinical grade NGS sample preparation. We are delighted to work with MPLN and furnish unparalleled quality and support to their needs," said Ivan Trifunovich, President and CEO of WaferGen.
The Seq-Ready™ TE MultiSample System enables one-step target enrichment and library preparation solution which addresses CLIA-certified clinical laboratories' significant unmet needs in sequencing-based testing by providing uniform coverage of targeted genes, yielding better test specificity and sensitivity. The superior performance of this new product is based on WaferGen's proprietary technology that relies on massively parallel singleplex PCR, where amplification is cleaner and better controlled, resulting in a more accurate variant calling.
WaferGen Bio-systems, Inc. is a life science company that offers innovative genomic solutions for clinical testing and research. The SmartChip MyDesign™ Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping. The SmartChip TE™ System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS). The Company now also offers the Apollo 324™ product line used in library preparation for NGS. These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.
For additional information, please see http://www.wafergen.com
Forward Looking Statements
Certain statements made in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage and our expectations concerning our competitive position and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
SOURCE: WaferGen Bio-systems, Inc.Copyright 2014 PR Newswire. All Rights Reserved